192 Results for "

ripk

" in MedChemExpress (MCE) Product Catalog:
Products (192)

192 Results for "ripk" in MCE Product Catalog:

  • Targets Recommended:
  • Recombinant Proteins Recommended:
110
110 Publications Verification
Art. -Nr.: HY-101872
CAS. Nr.: 1346546-69-7
Reinheit:  99.80%
Target:  

RIP kinase

Forschungsgebiete:  

Inflammation/Immunology

GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .
loading...
    loading...
110
110 Publications Verification
Art. -Nr.: HY-101872A
CAS. Nr.: 2703752-81-0
Reinheit:  99.21%
Target:  

RIP kinase

Forschungsgebiete:  

Inflammation/Immunology

GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury .
loading...
    loading...
44
44 Cited Publications
Art. -Nr.: HY-16591
CAS. Nr.: 1260251-31-7
Synonyms: TL32711
Target:  

IAP Apoptosis HIV

Forschungsgebiete:  

Cancer

Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.
loading...
    loading...
34
34 Cited Publications
Art. -Nr.: HY-14622A
CAS. Nr.: 852391-15-2
Reinheit:  99.65%
Synonyms: Necrostatin 1S; Nec-1S; 7-Cl-O-Nec1
Target:  

RIP kinase

Forschungsgebiete:  

Cancer

Necrostatin 2 racemate (Nec-1S), the Necrostatin-1 (HY-15760) stable, is a potent and specific RIPK1 inhibitor lacking the IDO-targeting effect .
loading...
    loading...
11
11 Cited Publications
Art. -Nr.: HY-14622
CAS. Nr.: 852391-19-6
Reinheit:  99.92%
Target:  

RIP kinase

Forschungsgebiete:  

Cancer

Necrostatin 2 is a potent necroptosis inhibitor. EC50 for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.
loading...
    loading...
8
8 Cited Publications
Art. -Nr.: HY-125402
CAS. Nr.: 1601496-05-2
Reinheit:  99.18%
Synonyms: GSK'843
Target:  

RIP kinase Apoptosis

Forschungsgebiete:  

Inflammation/Immunology

GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM. GSK-843 can be used for the research of inflammation .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-N1535
CAS. Nr.: 52617-37-5
Synonyms: Rubescensine B
Ponicidin (Rubescensine B) is an orally active RIPK1 inhibitor with a Kd value of 135 nM. Ponicidin inhibits the JAK2/STAT3 pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, suppresses inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing plaque deposition. Ponicidin can be used in studies related to hepatocellular carcinoma, Alzheimer's disease, and gastric cancer .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-107978
CAS. Nr.: 2141969-56-2
Reinheit:  99.57%
Target:  

RIP kinase

Forschungsgebiete:  

Inflammation/Immunology

RIPK-IN-4 is a selective RIPK2 inhibitor with an IC50 value of 3 nM. RIPK-IN-4 can be used for the research of inflammatory diseases .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-18937
CAS. Nr.: 1354825-58-3
Target:  

RIP kinase

Forschungsgebiete:  

Cancer

WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-N0546
CAS. Nr.: 260413-62-5
Synonyms: Nuezhenoside
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-111866
CAS. Nr.: 1801547-16-9
Reinheit:  99.89%
Target:  

PROTACs RIP kinase

Forschungsgebiete:  

Metabolic Disease

PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-131064
CAS. Nr.: 2361139-70-8
Reinheit:  99.19%
Target:  

RIP kinase

Forschungsgebiete:  

Inflammation/Immunology

RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC50 of 1.1 μM .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-156591
CAS. Nr.: 3032600-90-8
Reinheit:  99.76%
Forschungsgebiete:  

Others

PROTAC MLKL Degrader-1 is a selective MLKL PROTAC degrader with a DC50 of 2.4 μM. PROTAC MLKL Degrader-1 blocks necroptosis without modulating the phosphorylation of RIPK1 or RIPK3, and exhibits a linear correlation between MLKL levels and necroptotic cell death .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-171658
CAS. Nr.: 3070346-91-4
R1-ICR-5 is a highly selective RIPK1 PROTAC degrader. Mediated by VHL, R1-ICR-5 induces the degradation of RIPK1, which in turn dysregulates the TNFR1 and TLR3/4 signaling hubs, enhances the signaling outputs of NF-κB, MAPK and IFN, and simultaneously promotes RIPK3 activation and necroptosis (necroptosis). R1-ICR-5 can be used in the research of triple-negative breast cancer and skin inflammation .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-124793
CAS. Nr.: 319492-82-5
Reinheit:  98.79%
Forschungsgebiete:  

Infection

GAK inhibitor 49 is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 also shows binding to RIPK2 .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-124793A
CAS. Nr.: 2930378-91-7
Reinheit:  99.52%
Forschungsgebiete:  

Infection

GAK inhibitor 49 hydrochloride is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 hydrochloride also shows binding to RIPK2 .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-104021
CAS. Nr.: 2361146-30-5
Reinheit:  99.95%
Synonyms: GSK'840
Target:  

RIP kinase

Forschungsgebiete:  

Inflammation/Immunology

GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 0.9 nM, and inhibits kinase activity with an IC50 of 0.3 nM .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-158312
CAS. Nr.: 2540881-21-6
Reinheit:  99.80%
UH15-38 is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-158312A
UH15-38 TFA is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 TFA blocks IAV (influenza A virus)-activated necroptosis. UH15-38 TFA dampens IAV-induced lung injury .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-136789
CAS. Nr.: 2414572-47-5
Reinheit:  99.69%
Synonyms: BDTX-189
Target:  

EGFR

Forschungsgebiete:  

Cancer

Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity .
loading...
    loading...